title: Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer.
abstract: OBJECTIVE
  To compare markers of ovarian reserve between women exposed to cytotoxic chemotherapy for early stage breast cancer and matched controls.
  
  
  METHODS
  Cross-sectional evaluation of markers of ovarian reserve.
  
  
  METHODS
  Dana-Farber/Brigham and Women's Cancer Center, Massachusetts General Hospital, and Faulkner Hospital in Boston, MA.
  
  
  METHODS
  Breast cancer survivors with continued menses after chemotherapy were compared with age-matched, gravidity-matched controls.
  
  
  METHODS
  Antral follicle count (AFC), anti-Müllerian hormone (AMH), FSH, inhibin B (InB), and E(2) on day 2, 3, or 4 of the menstrual cycle. A Bonferroni correction was performed to correct for multiple comparisons.
  
  
  RESULTS
  Twenty survivors and 20 controls were evaluated; 50% of survivors were currently on tamoxifen. Median AFC was 6 for survivors and 9.5 for controls. There were significant differences between the two groups in AFC, AMH, and nonsignificant differences in FSH and InB, all indicating better ovarian reserve in controls. The AFC and AMH levels were highly correlated (r = 0.72). Survivors on tamoxifen had lower AFC, AMH, InB, and higher E(2) than nontamoxifen-treated survivors.
  
  
  CONCLUSIONS
  Premenopausal breast cancer survivors have diminished ovarian reserve compared with controls.
authors.affiliation: Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA 02115, USA. ahpartridge@partners.org
authors.forename: Ann H
authors.initials: AH
authors.lastname: Partridge
authors.forename: Kathryn J
authors.initials: KJ
authors.lastname: Ruddy
authors.forename: Shari
authors.initials: S
authors.lastname: Gelber
authors.forename: Lidia
authors.initials: L
authors.lastname: Schapira
authors.forename: Mary
authors.initials: M
authors.lastname: Abusief
authors.forename: Meghan
authors.initials: M
authors.lastname: Meyer
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Ginsburg
mesh_terms: D000328:Adult; D054304:Anti-Mullerian Hormone / Q000097:blood; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D015897:Comorbidity; D003430:Cross-Sectional Studies; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007247:Infertility, Female / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology; D007265:Inhibins / Q000097:blood; D008499:Medical Records; D008597:Menstrual Cycle; D009367:Neoplasm Staging; D006080:Ovarian Follicle / Q000187:drug effects / Q000502:physiology*; D017697:Premenopause; D017741:Survivors / Q000706:statistics & numerical data; D013629:Tamoxifen / Q000009:adverse effects*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D015415:Biomarkers; C422364:inhibin B; D013629:Tamoxifen; D004958:Estradiol; D007265:Inhibins; D054304:Anti-Mullerian Hormone; D005640:Follicle Stimulating Hormone